Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents

A series of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones were designed, synthesized and evaluated as selective human immunodeficiency virus type-1 reverse transcriptase (HIV-1 RT) enzyme inhibitors. The results of the HIV-1 RT kit and in vitro cell based assay showed that eight compounds effectively inhibited HIV-1 replication at 20–320 nM concentrations with minimal cytotoxicity in MT-4 as well as in CEM cells.

In the present study, synthesis of a new series of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-one derivatives and evaluation of their activity against HIV-1 reverse transcriptase enzyme are described.Figure optionsDownload as PowerPoint slide